Fabry Disease Treatment Market Share, Trends And Growth By 2034

Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics

What Is the Predicted Market Size and CAGR of the Fabry Disease Treatment Market by the End of the 2029?
The fabry disease treatment market size has grown strongly in recent years. It will grow from $2.09 billion in 2024 to $2.27 billion in 2025 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing awareness and diagnosis rates, increasing adoption of enzyme replacement therapies, increasing use of chaperone therapies, increasing healthcare infrastructure, rise in investment in rare disease research, increasing population, and increasing regulatory incentives for orphan drugs.

The fabry disease treatment market size is expected to see strong growth in the next few years. It will grow to " $3.13 billion in 2029 at a compound annual growth rate (CAGR) of 8.3%. The growth in the forecast period can be attributed to increasing prevalence of the disease, rising awareness and diagnosis rates, expanding healthcare infrastructure, growing investment in rare disease research, growing patient awareness, and expanding reimbursement policies. Major trends in the forecast period include advancements in gene therapy, advancements in enzyme replacement therapies, advancements in diagnostic techniques, advancements in novel therapies, and integration of digital health technologies for patient management.

Get your free report sample today:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16421&type=smp

Which Factors Are Contributing Most to the Expansion of the Fabry Disease Treatment Market?
The increasing prevalence of renal diseases is expected to propel the growth of the fabry disease treatment market going forward. Renal diseases, also known as kidney diseases, refer to any conditions impairing the kidneys' function. The cases of renal diseases are growing due to genetic predispositions, lifestyle choices, environmental factors, and underlying health conditions. Fabry disease is caused by the accumulation of globotriaosylceramide (Gb3) in kidney cells, leading to damage and dysfunction, highlighting the critical need for early detection and intervention to prevent kidney complications. For instance, in December 2023, the Australian Bureau of Statistics, an Australian government agency, reported that 246,200 people (1.0% of the population) had kidney disease in 2022, representing a 0.2% increase over the past decade. Therefore, the increasing prevalence of renal diseases is driving the growth of the fabry disease treatment market.

Which Key Segments Are Included in the Fabry Disease Treatment Market Analysis?
The fabry disease treatmentmarket covered in this report is segmented –

1) By Treatment: Substrate Reduction Therapy; Enzyme Replacement Therapy; Chaperone Treatment; Other Treatments
2) By Route Of Administration: Oral Route; Intravenous Route
3) By Disease Severity: Classic Fabry Disease; Late-Onset Fabry Disease
4) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Subsegments:
1) By Substrate Reduction Therapy: Migalastat Hydrochloride (Galafold); Other Substrate Reduction Therapies
2) By Enzyme Replacement Therapy: Agalsidase Beta (Fabrazyme); Agalsidase Alfa (Replagal); Other Enzyme Replacement Therapies
3) By Chaperone Treatment: Migalastat Hydrochloride (Galafold)
4) By Other Treatments: Gene Therapy; Symptomatic Treatment

What New Market Trends Are Emerging in the Fabry Disease Treatment Market?
Major companies operating in the Fabry disease treatment market are developing plant cell-based treatments to enhance therapeutic efficacy, reduce treatment costs, and improve patient outcomes through innovative and sustainable approaches. Plant cell-based treatment for fabry disease involves using plant cells to produce deficient enzymes in individuals with fabry disease. These plant-derived enzymes can be used as a therapeutic option to replace the missing or defective enzymes in the body, aiming to alleviate symptoms and improve the health of patients affected by Fabry disease. For instance, in May 2023, Chiesi Global Rare Diseases, an Italy-based pharmaceutical company, and Protalix BioTherapeutics Inc., an Israel-based pharmaceutical company, received approval for the ELFABRIO. ELFABRIO presents an alternative treatment choice for individuals with Fabry disease. It is an enzyme replacement therapy (ERT) where the recombinant human a-Galactosidase-A enzyme is produced in plant-cell culture and modified with PEGylation to extend its half-life significantly. This treatment reduces frequency, enhances convenience, and improves the overall management of Fabry disease symptoms, enhancing patient quality of life.

Who Are the Top Industry Players Driving the Fabry Disease Treatment Market Growth?
Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation

Get the detailed fabry disease treatment market report today
https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report

Which Regional Markets Offer the Most Promising Growth Opportunities for the Fabry Disease Treatment Market?
North America was the largest region in the fabry disease treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company